|
Aspirin exacerbated respiratory disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
Decreased PGE2 signaling through the EP2 receptor in patients with AERD leads to an increase in leukotriene synthesis and signaling.
|
30516547 |
2019 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Understanding the role and mechanisms of action of the EP2 receptor, and its importance in targeted therapy, may help identify novel methods to improve management of numerous types of cancer.
|
29956743 |
2018 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Thus, targeting the EP2 receptor with small molecules could be a therapeutic strategy for treating inflammatory diseases and cancer.
|
30398879 |
2018 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Understanding the role and mechanisms of action of the EP2 receptor, and its importance in targeted therapy, may help identify novel methods to improve management of numerous types of cancer.
|
29956743 |
2018 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Thus, targeting the EP2 receptor with small molecules could be a therapeutic strategy for treating inflammatory diseases and cancer.
|
30398879 |
2018 |
|
Aspirin exacerbated respiratory disease
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
These studies suggest that the EP2 promotor is under epigenetic control, and one explanation for PGE2 resistance in AERD is an epigenetically mediated reduction of EP2 receptor expression, which could contribute to the refractory nasal polyposis typically observed in this syndrome.
|
26051534 |
2016 |
|
Aspirin exacerbated respiratory disease
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Alterations in IL-1RI, COX-2, and mPGES-1 expression that were found in NP-AERD fibroblasts were corrected when EP2 receptor expression was normalized by transfection of NP-AERD fibroblasts.
|
26560040 |
2016 |
|
Malignant Neoplasms
|
0.030 |
PosttranslationalModification
|
group |
BEFREE |
An examination of 3 triple negative, 3 ductal carcinoma in situ and 3 invasive ductal carcinoma samples revealed that there was no change in EP2 promoter methylation status between normal and cancer associated stroma, despite observed differences in relative mRNA levels.
|
22929011 |
2012 |
|
Primary malignant neoplasm
|
0.030 |
PosttranslationalModification
|
group |
BEFREE |
An examination of 3 triple negative, 3 ductal carcinoma in situ and 3 invasive ductal carcinoma samples revealed that there was no change in EP2 promoter methylation status between normal and cancer associated stroma, despite observed differences in relative mRNA levels.
|
22929011 |
2012 |
|
Status Epilepticus
|
0.020 |
Biomarker
|
disease |
BEFREE |
A rat model of organophosphate-induced status epilepticus and the beneficial effects of EP2 receptor inhibition.
|
30818067 |
2020 |
|
Glaucoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Omidenepag isopropyl is a selective prostaglandin EP2 receptor agonist which was approved on September 21, 2018, in Japan for the treatment of glaucoma and OHT.
|
31250842 |
2019 |
|
Seizures
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Utilizing a bioavailable and brain-permeant compound, TG6-10-1, we found that pharmacological inhibition of EP2 receptor after a one-hour episode of kainate-induced status epilepticus (SE) in mice reduced seizure-promoted functional deficits, cytokine induction, reactive gliosis, blood-brain barrier impairment, and hippocampal damage.
|
30763657 |
2019 |
|
Status Epilepticus
|
0.020 |
Biomarker
|
disease |
BEFREE |
Utilizing a bioavailable and brain-permeant compound, TG6-10-1, we found that pharmacological inhibition of EP2 receptor after a one-hour episode of kainate-induced status epilepticus (SE) in mice reduced seizure-promoted functional deficits, cytokine induction, reactive gliosis, blood-brain barrier impairment, and hippocampal damage.
|
30763657 |
2019 |
|
Amyotrophic Lateral Sclerosis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Pathophysiological role of prostaglandin E2-induced up-regulation of the EP2 receptor in motor neuron-like NSC-34 cells and lumbar motor neurons in ALS model mice.
|
28687401 |
2018 |
|
Seizures
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
In this context, while the activation of the PGE<sub>2</sub> EP2 receptor causes early neuroprotective and late neurotoxic effects, the role of EP2 receptor in seizures remains unclear.
|
28645087 |
2017 |
|
Tumor Progression
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Overall, PGE<sub>2</sub> signaling via host EP2 receptors affected a large number of different genes involved in tumor progression based on signaling between host stroma and tumor cells, which caused reduced tumor growth.
|
28123585 |
2017 |
|
Glaucoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The goal of this study was to investigate the effects of F prostanoid (FP) and EP2 receptor activation on the myofibroblast transition of primary trabecular meshwork (TM) cells, which could be a causal mechanism of TM dysfunction in glaucoma.
|
27082296 |
2016 |
|
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Taking advantage of our recently identified novel selective antagonist for the EP2 (PTGER2) subtype of PGE(2) receptor, we demonstrated that EP2 receptor activation could promote prostate cancer cell growth and invasion in vitro, accompanied by upregulation of the tumor-promoting inflammatory cytokines, such as IL-1β and IL-6.
|
23192657 |
2013 |
|
Amyotrophic Lateral Sclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis.
|
18825663 |
2008 |
|
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Our results indicated that COX2-PGE2 pathway may be involved in H. pylori-associated uPA and uPAR induction, and that COX-2 inhibitor or EP2 receptor antagonist may inhibit angiogenesis and tumor invasion via suppression of the uPA system.
|
18466392 |
2008 |
|
Tumor Progression
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Thus, down-regulation of EP(2) receptors represents a potential mechanism for neoplastic progression to an invasive phenotype.
|
12466123 |
2002 |
|
Cerebral Infarction
|
0.010 |
Biomarker
|
disease |
BEFREE |
PGE<sub>2</sub> signaling via the neuronal EP2 receptor increases injury in a model of cerebral ischemia.
|
31036664 |
2019 |
|
Hyperparathyroidism
|
0.010 |
Biomarker
|
disease |
BEFREE |
Furthermore, PGE2 or EP2 agonist (butaprost) directly stimulated hyperparathyroidism, whereas EP2 receptor antagonist or cyclic adenosine monophosphate inhibitor attenuated the hyperparathyroidism promoted by PGE2 or butaprost.
|
29982796 |
2019 |
|
Cerebrovascular accident
|
0.010 |
Biomarker
|
group |
BEFREE |
Taken together with a precedent that inhibition of EP2 signaling is protective in inflammatory neurodegeneration, these data lend support to translational approaches targeting the EP2 receptor to reduce inflammation and neuronal injury that occur after stroke.
|
31036664 |
2019 |
|
Glaucoma and ocular hypertension
|
0.010 |
Biomarker
|
disease |
BEFREE |
Omidenepag isopropyl is a selective prostaglandin EP2 receptor agonist which was approved on September 21, 2018, in Japan for the treatment of glaucoma and OHT.
|
31250842 |
2019 |